Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Mepilex Cesarean Delivery Trial

NCT: NCT07066254 · NOT_YET_RECRUITING

NCT IDNCT07066254
StatusNOT_YET_RECRUITING
Start Date2026-04
Completion2027-02

Brief Summary

The goal of this clinical trial is to learn whether using a silver-containing antimicrobial foam dressing (Mepilex Ag) can help prevent surgical site infections in patients undergoing cesarean delivery. The main questions it aims to answer are: 1. Does Mepilex Ag reduce the rate of surgical site infections after cesarean delivery? 2. Is Mepilex Ag more effective than standard wound dressings in preventing infection? Researchers will compare those who receive the Mepilex Ag dressing to those who receive the standard dressing to see if the silver impregnated antimicrobial foam dressing lowers infection rate. Participants will: 1. Undergo a routine cesarean delivery as per usual obstetric indication 2. Be randomly assigned to receive either a silver-containing foam dressing or a standard dressing after surgery 3. Be monitored for wound complications and signs of infection during the postpartum period

Frequently Asked Questions

What is The Mepilex Cesarean Delivery Trial?

The Mepilex Cesarean Delivery Trial is a clinical trial registered under NCT07066254. Current status: NOT_YET_RECRUITING.

What is the status of NCT07066254?

The current status of NCT07066254 (The Mepilex Cesarean Delivery Trial) is: NOT_YET_RECRUITING.

When did The Mepilex Cesarean Delivery Trial start?

The Mepilex Cesarean Delivery Trial started on 2026-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.